Tumor Profiling for Prognostic Assessment

Predicting the outcomes of cancer remains challenging, despite the advancement of technologies that are available in the clinic. A growing number of scientists are investigating the use of tumor profiling in order to further our ability to diagnose and predict outcomes in cancer. tumor profiling is a prognostic tool to predict recurrence risk or response to adjuvant therapies and is being introduced into clinical practice.

Tumor Profiling at Creative Biolabs

With an experienced team of in-house experts in tumor profiling, Creative Biolabs has developed a full pipeline to provide our clients with a highly customizable solution. We apply next-generation sequencing (NGS), in situ hybridization (ISH), polymerase chain reaction (PCR), immunohistochemistry (IHC), and microarrays for tumor profiling. Our seasoned scientists will work with our clients to develop a complete solution for prognostic assessment from project design to in-depth analysis.

Fig.1 Technologies for tumor profiling, which could be used for prognostic assessment. (Creative Biolabs)

Highlights

• prognostic assessment methods with good sensitivity and specificity
• Detection and quantification of low-frequency genomic alterations
• Emphasizing the high degree of heterogeneity reported within tumors
• Analyzing the compound effect of multiple mutations on disease onset and progression

Partial Result Display

• Cluster analysis by qPCR

Fig.2 Unsupervised clustering. (Reichert, et al., 2021)

• Microarray profile

Fig.3 Four examples of Nimblegen 4×72 K comparative genomic hybridisation-array (array-CGH) profiles. (Cassoux, et al., 2014 )

Published Data

Paper Title: Multigene profiling of circulating tumor cells (CTCs) for prognostic assessment in treatment-naïve metastatic hormone-sensitive prostate cancer (mHSPC)

Published: 2022

Background and Results: The development of personalized therapeutic approaches has been hindered by the substantial biological heterogeneity of metastatic prostate cancer. Therefore, it is difficult to assess the prognosis of metastatic hormone-sensitive prostate cancer. Gene expression profiling in this paper showed that the presence of CTCs was greater in CHAARTED high-volume patients compared to low-volume patients. High-volume disease and the presence of CTC were found to be independently associated with the risk of non-response at 7 months. What's more, AR, DSG2, KLK3, MDK, and PCA3 were identified to be genes predictive of non-response by pooled gene expression from CTCs of pre-androgen deprivation therapy (ADT) samples.

Fig.4 Heatmap of MiCoPilot patient gene expression prior to initiation of ADT. (Reichert, et al., 2021)

Creative Biolabs has developed a full pipeline to integrate tumor profiles for prognostic assessment. By applying this pipeline, prognoses have been assessed in several cancers. Please feel free to contact us to get more detailed information.

References

1. Cassoux, N.; et al. Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. British Journal of Ophthalmology. 2014, 98(6): 769-74.
2. Reichert, Z.R.; et al. Multigene profiling of circulating tumor cells (CTCs) for prognostic assessment in treatment-naïve metastatic hormone-sensitive prostate cancer (mHSPC). International Journal of Molecular Sciences. 2021, 23(1): 4.

For Research Use Only | Not For Clinical Use